Clinical trial · Interventional
Maekmoondong-tang on Post-operative Cough in Patients With Lung Cancer
Efficacy and Safety Evaluation of Maekmoondong-tang on Post-operative Cough in Patients With Lung Cancer -Randomized, Double-blind, Placebo-controlled Clinical Trial
NCT03384667CI-TRIAL-00031857unknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the present study is to evaluate the efficacy and safety of Maekmoondong-tang on post-operative cough in patients with lung cancer. A randomized, double-blind, placebo-controlled trial will be conducted.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Postoperative Cough | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Maekmoondong-tang | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- MMDT group
- interventionNames
- Drug: Maekmoondong-tang
- type
- PLACEBO_COMPARATOR
- label
- Placebo group
- interventionNames
- Drug: Placebo
Primary outcomes (1)
- measure
- Leicester Cough Questionnaire (LCQ)
- timeFrame
- Day 0 to Day 28
- description
- Questionnaire used to measure quality of life in cough patients. The total score of LCQ is 3 to 21, and a higher score means a better quality of life.
Secondary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Adults over 20 years old. * Patients undergone segmentectomy or lobectomy for lung cancer within 1 month * Patients who do not or poorly respond to one week administration of common antitussive agents. * Eastern Cooperative Oncology Group(ECOG) 0 to 2 * Participant is willing and able to give informed consent for participation in the study Exclusion Criteria: * Patients undergoing adjuvant chemotherapy. * Patients who have been diagnosed with acute respiratory disease within 1 month. * Patients who have been diagnosed with bronchial asthma or bronchiectasis within 1 year * Patients taking Angiotensin Converting Enzyme Inhibitor * Patients with pseudoaldosteronism. * Participants who have known prior hypersensitivity to any investigational product component * Patient with acute or chronic infections requiring treatment (active HAV, HBV, HCV, HIV, TB) * Pregnant or lactating females * Women of childbearing potential * Patient who do not agrees to use effective means of contraception and not to donate sperm during the trial and up to 1 month after final administration * Patient who participated other clinical trials of medicine or medical devices within 1 month * Individuals who are judged inappropriate for the study by investigator
References
Publications (0)
Data not yet available
No reference posted for this study.